Αποτελέσματα Αναζήτησης
Insulin therapy is the mainstay of treatment for clinical DM. The guidelines provide rec-ommendations for each insulin formulation currently available for use in dogs and cats, the choice of which is generally based on efficacy and duration of effect in the respective species. Also discussed are non-insulin therapeutic medications
An example protocol for regular insulin infusion in dogs (up to 2.2 U/kg, IV CRI, every 24 hours, titrated to effect) or cats (up to 1.1 U/kg, IV CRI, every 24 hours, titrated to effect) is summarized in the table Regular Insulin Constant-Rate Infusion for Diabetic Ketoacidosis in Dogs and Cats.
Insulin therapy is still the primary therapy for all diabetic dogs and cats. Several insulin options are available for each species, including veterinary registered products and human insulin preparations. The insulin chosen depends on the individual patient’s requirements. Intermediate-acting insulin is usually the first choice for dogs, and ...
10 Μαΐ 2019 · Most dogs are well controlled on insulin at an average dose of 0.5 U/kg q 12 hr with a range of 0.2–1.0 U/kg.The duration of action is close to 12 hr in most dogs, and the amorphous component of the insulin helps to minimize postprandial hyperglycemia.
Doses of insulin are measured in units: 40 IU/ml insulin contains 40 International Units (IU) per millilitre (ml). Use Caninsulin with U-40 syringes only to avoid dosing errors when administering Caninsulin to dogs. Human insulin is formulated at a concentration of 100 IU / ml.
5 Νοε 2019 · The currently published protocols for insulin therapy for DKA are outlined below. Readers are encouraged to review the primary publications to decide which protocols may work best for individual patients. Low dose intramuscular insulin therapy for diabetic ketoacidosis in dogs. Chastain CB, Nichols CE.
10 Μαΐ 2019 · Other insulin types and other therapeutics can be used in dogs and cats based on the patient’s response to first-line insulin therapy and associated recommendations, as discussed in the “Monitoring” section of the guidelines.
